engleski

Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer- chemotherapy toxicity and prognostic value

Cancer cachexia and sarcopenia are frequently observed in non-small lung cancer patients and associated with poor survival. The purpose of our study was to evaluate prevalence of cachexia and sarcopenia in patients with diagnosed advanced NSCLC and their impact on chemotherapy toxicity and time to disease progression, as well as predictive value of several biochemical markers. One hundred patients with advanced IIIB or IV stage of NSCLC that were to start with systemic chemotherapy were recruited in the study. We provided anthropometric and biochemical data and body composition measurements for each patient. Muscle mass was measured by the analysis of electronically stored CT images using lumbar vertebral landmark (L3). Measured muscle area in this region correspond to whole-body tissue quantities. The prevalence of cachexia in our study was 69%, and sarcopenia was present in 47% of patients. We found statistically significant difference between CRP, IL- 6 and albumin concentration in cachectic patients and non-cachectic patients. In our study, cachexia and sarcopenia were not predictors of chemotoxicity and survival, but albumin concentration has been shown to be the predictive factor of both chemotoxicity and survival. Biochemical parameters, such as CRP and albumin level have shown to be of more important predictive value in chemotherapy toxicity and survival probability than cachexia and sarcopenia.

cancer cachexia ; sarcopenia ; non-small cell lung cancer ; chemotherapy toxicity

nije evidentirano